Preclinical studies by us and others provided a strong rationale of evaluating a CD38‐targeting antibody alone or in combination in MM patients with relapsed/refractory or newly diagnosed disease (Tables 1, 2, 3). Here, CD38 is linked to Miyoshi myopathy.